# Initiation of Hybrid Closed‐Loop Artificial Pancreas System Improves Glycemic Control in a Hospitalized Type 1 Diabetes: A Case Report and Review

## TL;DR

This case report shows that a hybrid artificial pancreas system improves blood sugar control in hospitalized type 1 diabetes patients compared to traditional insulin injections.

## Contribution

Demonstrates the feasibility and improved glycemic control of a hybrid closed-loop artificial pancreas system in hospitalized T1DM patients.

## Key findings

- The Android-HCL system showed better intraday glucose control compared to multiple insulin injections.
- The system significantly reduced Grade 2 hypoglycemia events.
- Artificial pancreas systems may be preferable to conventional insulin therapy for hospitalized T1DM patients.

## Abstract

To observe the efficacy and safety of artificial pancreas (Android‐hybrid closed‐loop [HCL] system) in patients with type 1 diabetes mellitus (T1DM), and to compare it with insulin multi‐injection therapy.

A patient with long course of type 1 diabetes was treated with multiple injections of insulin, Android‐HCL therapy, and sequential multiple injections of insulin. The intraday glucose fluctuation (especially after lunch, before sleep, and during sleep) of the Android‐HCL system was significantly superior to that of the sequential multi‐injection insulin therapy. The administration of artificial pancreas system (APS) could significantly reduce the occurrence of Grade 2 hypoglycemia events.

Artificial pancreases are feasible for inpatients with type 1 diabetes and may be preferable to conventional insulin therapy.